- Home
- PSNL vs EYEN Comparison
PSNL vs EYEN Comparison
Compare PSNL & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- EYEN
- Stock Information
- Founded
- PSNL 2011
- EYEN 2014
- Country
- PSNL United States
- EYEN United States
- Employees
- PSNL N/A
- EYEN N/A
- Industry
- PSNL Medical Specialities
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- EYEN Health Care
- Exchange
- PSNL Nasdaq
- EYEN Nasdaq
- Market Cap
- PSNL 321.1M
- EYEN 38.2M
- IPO Year
- PSNL 2019
- EYEN 2018
- Fundamental
- Price
- PSNL $5.19
- EYEN $0.55
- Analyst Decision
- PSNL Strong Buy
- EYEN Strong Buy
- Analyst Count
- PSNL 4
- EYEN 2
- Target Price
- PSNL $6.81
- EYEN $12.00
- AVG Volume (30 Days)
- PSNL 439.4K
- EYEN 879.0K
- Earning Date
- PSNL 11-06-2024
- EYEN 11-11-2024
- Dividend Yield
- PSNL N/A
- EYEN N/A
- EPS Growth
- PSNL N/A
- EYEN N/A
- EPS
- PSNL N/A
- EYEN N/A
- Revenue
- PSNL $80,027,000.00
- EYEN $31,405.00
- Revenue This Year
- PSNL $10.85
- EYEN $50,309.30
- Revenue Next Year
- PSNL $8.77
- EYEN $421.63
- P/E Ratio
- PSNL N/A
- EYEN N/A
- Revenue Growth
- PSNL 19.20
- EYEN N/A
- 52 Week Low
- PSNL $0.89
- EYEN $0.37
- 52 Week High
- PSNL $7.20
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- EYEN 52.60
- Support Level
- PSNL $4.54
- EYEN $0.52
- Resistance Level
- PSNL $5.35
- EYEN $0.59
- Average True Range (ATR)
- PSNL 0.30
- EYEN 0.05
- MACD
- PSNL 0.05
- EYEN 0.01
- Stochastic Oscillator
- PSNL 84.71
- EYEN 66.45
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.